Tenpoint Therapeutics
Develops treatments to rejuvenate vision in the aging eye
$235MSeries B
Role not disclosedEL
EQT Life Sciences
Activity from announced rounds
Activity in this selectionUnited States · Oct 9, 2026 · Jan 1, 2026
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $338M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionKinaset Therapeutics
Develops inhaled therapies for severe respiratory diseases
$103MSeries B
Role not disclosed